Guangzhou Jiayue Pharmaceutical Technology Co., Ltd, a Chinese pharmaceutical company, has entered into a licensing agreement with Erasca (NASDAQ: ERAS), a US-based biopharmaceutical company. Under the terms of this agreement, Erasca has been granted exclusive rights to research, develop, and commercialize Jiayue Pharma’s pan-RAS (ON) inhibitor, JYP0015, excluding China mainland, Hong Kong, and Macau.
As part of the deal, Erasca will make an initial payment of USD 20 million to Jiayue Pharma, with further commitments to potential milestone payments totaling USD 345 million and global exercise payments. The agreement also includes tiered royalties based on net sales.
JYP0015 has demonstrated promising results in various preclinical RAS mutation drug efficacy models, showcasing high anti-tumor activity. The compound has also exhibited favorable drug metabolism and pharmacokinetic (DMPK) properties, oral bioavailability, and a favorable safety profile.- Flcube.com
